Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, a holding subsidiary of Kelun Pharmaceutical (SZ:002422), announced on Monday that the new drug application (NDA) for its small molecule rearranged during transfection (RET) kinase inhibitor A400 (EP0031) has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
The product is intended for the treatment of adult patients with RET-fusion positive locally advanced, or metastatic non-small cell lung cancer (NSCLC).
This acceptance for review is based on positive results from the two pivotal Phase 2 cohorts of the KL400-I/II-01 study for both 1L and 2L+ advanced RET-fusion positive NSCLC.
bioMérieux files FDA application for rapid vaginitis diagnostic panel
Racura Oncology doses first patient in Phase 1 lung cancer trial
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Kither Biotech completes Phase 1 KIT2014 clinical study
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Precigen and the RRPF recognise International RRP Awareness Day